Acquired hemophilia A following BNT162b2 mRNA COVID-19 vaccination

DOI Web Site PubMed
  • SENDA Ayami
    Department of Hematology and Oncology, Osaka University
  • SAITO Hideaki
    Department of Hematology and Oncology, Osaka University Department of Hematology, Daini Osaka Police Hospital
  • KUSAKABE Shinsuke
    Department of Hematology and Oncology, Osaka University
  • YOSHIDA Koki
    Department of Hematology and Oncology, Osaka University
  • SHIBATA Kumi
    Department of Hematology and Oncology, Osaka University
  • KIDA Shuhei
    Department of Hematology and Oncology, Osaka University
  • TODA Jun
    Department of Hematology and Oncology, Osaka University Department of Hematology, National Hospital Organization Osaka National Hospital
  • HINO Akihisa
    Department of Hematology and Oncology, Osaka University
  • UEDA Tomoaki
    Department of Hematology and Oncology, Osaka University
  • FUJITA Jiro
    Department of Hematology and Oncology, Osaka University
  • FUKUSHIMA Kentaro
    Department of Hematology and Oncology, Osaka University
  • YOKOTA Takafumi
    Department of Hematology and Oncology, Osaka University Department of Hematology, Osaka International Cancer Institute
  • KASHIWAGI Hirokazu
    Department of Hematology and Oncology, Osaka University Department of Blood Transfusion, Osaka University Hospital
  • HOSEN Naoki
    Department of Hematology and Oncology, Osaka University

Bibliographic Information

Other Title
  • BNT162b2 mRNA COVID-19ワクチン接種後に発症した後天性血友病A
  • BNT162b2 mRNA COVID-19ワクチン接種後に発症した後天性血友病A : 第116回近畿血液学地方会 優秀演題
  • BNT162b2 mRNA COVID-19 ワクチン セッシュ ゴ ニ ハッショウ シタ コウテンセイ ケツユウビョウ A : ダイ116カイ キンキ ケツエキガク チホウカイ ユウシュウ エンダイ

Search this article

Abstract

<p>Acquired hemophilia A (AHA) is a rare disease characteized by bleeding symptoms caused by decreased factor VIII activity due to the appearance of inhibitors to factor VIII triggered by malignancy or collagen disease. An 86-year-old woman developed purpura on her extremities after the first dose of the BNT162b2 mRNA COVID-19 vaccine. This symptom subsided after a few days. After the second dose of the BNT162b2 mRNA COVID-19 vaccine, purpura appeared again, and the patient was referred to our hospital Her APTT was remarkably prolonged to 110 seconds, and a cross-mixing test revealed an inhibitor pattern. Since FVIII activity was <1% and FVIII inhibitor was 51.6 BU, she was diagnosed with AHA. Prednisolone therapy was started, and coagulative complete remission was achieved. Because acquired hemophilia can develop after mRNA COVID-19 vaccination, as in this case, it is critical to monitor the appearance of bleeding symptom.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 64 (1), 35-41, 2023

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top